کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
1219921 | 1494549 | 2015 | 14 صفحه PDF | دانلود رایگان |
• Anti-osteoporotic activity of Ca-SGP is reported for the first time.
• Ca-SGP promoted osteogenesis.
• Ca-SGP increased OPG/RANKL ratio in MC3T3-E1 cells and bilateral ovariectomized rats.
• Ca-SGP improved tibia BMD of osteoporotic rats induced by bilateral ovariectomy.
• Ca-SGP is a novel and significant functional factor for the treatment of osteoporosis.
The anti-osteoporotic activities of a sialoglycoprotein isolated from the eggs of Carassius auratus (Ca-SGP). Ca-SGP was composed of 14.33% protein, 62.81% hexose, and 19.72% N-acetylneuraminic acid (Neu5Ac). In vitro experimental results showed that Ca-SGP significantly increased MC3T3-E1 pre-osteoblastic cells' proliferation activities, promoted cell differentiation and mineralization as evidenced by increasing the contents or activities of major markers, i.e. collagen type I (COL I), osteocalcin (OCN), alkaline phosphatase (ALP) and bone nodules. Ca-SGP significantly augmented protein expressions and secretions of bone morphogenetic protein 2 (BMP-2) and osteoprotegerin (OPG), meanwhile, decreased that of receptor activator of nuclear factor κB ligand (RANKL). In vivo experimental data further revealed that Ca-SGP significantly reduced bone turnover rates, increased serum OPG/RANKL ratio and enhanced tibia bone mineral density (BMD) in the model rats of ovariectomized (OVX)-induced osteoporosis. These results suggest that Ca-SGP could improve osteoporosis by promoting osteogenesis and inhibiting bone resorption via increasing OPG/RANKL ratio, which indicates that Ca-SGP is a potential candidate functional factor for osteoporosis prevention.
Journal: Journal of Functional Foods - Volume 15, May 2015, Pages 137–150